NCT00423280View on ClinicalTrials.gov

Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)

PHASE2UnknownINTERVENTIONAL

Enrollment

66

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Coronary Artery Disease

Interventions

DRUG

6R-BH4

6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo

Trial Locations (1)

OX3 9DU

RECRUITING

Department of Cardiovascular Medicine, University of Oxford, Oxford

Sponsors

Collaborators (1)

BioMarin Pharmaceutical

All Listed Sponsors

collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

University of Oxford

OTHER